STOCK TITAN

atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

atai Life Sciences, a clinical-stage biopharmaceutical company, will announce its second quarter 2022 financial results on August 15, 2022. The firm is focused on innovating treatments for mental health disorders, including depression and anxiety. A video interview with management will be available at 8:30 a.m. ET on the same day, with the recording to be accessible on their website. Founded in 2018, atai aims to accelerate drug development through a unique business model that integrates funding and regulatory expertise to tackle mental health challenges.

Positive
  • Plans to announce second quarter 2022 results, indicating ongoing business activity.
  • Focus on developing transformative treatments for mental health disorders.
Negative
  • None.

NEW YORK and BERLIN, Aug. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, plans to announce its second quarter 2022 financial results and business update on Monday, August 15, 2022.

A video interview with atai management will be available at 8:30 a.m. (ET) at https://vimeo.com/atailifesciences. The archived video interview will be available in the “Events” section of the atai website at https://www.atai.life/.

About atai Life Sciences

atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

atai's business model combines funding, technology, scientific, and regulatory expertise with a focus on innovative compounds, including psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies to achieve clinically meaningful and sustained behavioral change in mental health patients.

atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit https://www.atai.life/.

Contact Information

Investor Contact:
Greg Weaver
Chief Financial Officer
Email: IR@atai.life

Media Contact:
Allan Malievsky
Senior Director, External Affairs
Email: allan@atai.life


FAQ

When will atai Life Sciences announce its second quarter 2022 financial results?

atai Life Sciences will announce its second quarter 2022 financial results on August 15, 2022.

What is atai Life Sciences' focus in the biopharmaceutical industry?

atai Life Sciences aims to transform the treatment of mental health disorders, including depression, anxiety, and addiction.

Where can I find the video interview with atai management?

The video interview with atai management will be available at 8:30 a.m. ET on August 15, 2022, on their Vimeo channel.

What compounds is atai Life Sciences working on?

atai Life Sciences works on innovative compounds, including psychedelic therapy and drugs with differentiated safety profiles.

ATAI Life Sciences N.V. Common Shares

NASDAQ:ATAI

ATAI Rankings

ATAI Latest News

ATAI Stock Data

273.52M
151.01M
9.99%
26.83%
5.62%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BERLIN